• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    11/12/24 5:56:48 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $STOK alert in real time by email
    SC 13G/A 1 UnitedStates_13G__StokeThera.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Stoke Therapeutics Inc (Title of Class of Securities) Common Stock (CUSIP Number) 86150R107 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 86150R107 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 70,387 (7) Sole dispositive power 2,655,464 (8) Shared dispositive power 103,783 (9) Aggregate amount beneficially owned by each reporting person 2,759,247 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 5.24% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: Stoke Therapeutics Inc Item 1(b) Address of issuer's principal executive offices: 45 Wiggins Avennue Bedford, MA 01730 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 86150R107 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 2,759,247 (b) Percent of class: 5.24% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 2,759,247 (b) Percent of class: 5.24% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 70,387 (iii) Sole power to dispose or to direct the disposition of: 2,655,464 (iv) Shared power to dispose or to direct the disposition of: 103,783 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications By signing below I certify that, to the best of his/her knowledge and belief, t* he securities referred to above were not acquired and are not held for the pur* pose of or with the effect of changing or influencing the control of the issuer* of the securities and were not acquired and are not held in connection with or* as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: November 12, 2024 THE VANGUARD GROUP By: /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration
    Get the next $STOK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STOK

    DatePrice TargetRatingAnalyst
    12/20/2024$24.00Buy
    Chardan Capital Markets
    10/14/2024$18.00Outperform
    Leerink Partners
    3/26/2024Market Perform → Outperform
    TD Cowen
    11/20/2023Neutral
    JP Morgan
    7/25/2023Outperform → Market Perform
    TD Cowen
    5/1/2023$9.00 → $12.00Underperform → Neutral
    BofA Securities
    4/26/2023$24.00Buy
    Canaccord Genuity
    1/6/2023$22.00 → $9.00Buy → Underperform
    BofA Securities
    More analyst ratings

    $STOK
    SEC Filings

    See more
    • SEC Form 10-Q filed by Stoke Therapeutics Inc.

      10-Q - Stoke Therapeutics, Inc. (0001623526) (Filer)

      5/13/25 4:05:31 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)

      5/13/25 7:05:08 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Stoke Therapeutics Inc.

      144 - Stoke Therapeutics, Inc. (0001623526) (Subject)

      5/1/25 4:45:41 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

      Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 1:25 p.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. About Stoke Therapeutic

      5/29/25 7:30:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

      – Regulatory alignment achieved for Phase 3 EMPEROR study of zorevunersen, a potential first-in-class disease-modifying medicine for Dravet syndrome; Study start anticipated in 2Q 2025 – – Zorevunersen collaboration with Biogen brings leading capabilities for commercializing high value, disease-modifying medicines for rare genetic diseases; Stoke retains full rights in the United States, Canada, and Mexico – – As of March 31, 2025, the Company had $380.3 million in cash, cash equivalents, and marketable securities, anticipated to fund operations beyond 2H 2027 Phase 3 data and into launch readiness projected to mid-2028 – Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company

      5/13/25 7:00:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

      Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 8:45 a.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. About Stoke The

      4/1/25 4:30:00 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

      SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

      11/14/24 9:00:58 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Stoke Therapeutics Inc.

      SC 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)

      11/14/24 4:24:49 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

      SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

      11/14/24 9:00:12 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF MEDICAL OFFICER Ticho Barry sold $266,953 worth of shares (26,631 units at $10.02), decreasing direct ownership by 44% to 33,998 units (SEC Form 4)

      4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

      5/5/25 4:08:50 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Levin Arthur A converted options into 1,210 shares (SEC Form 4)

      4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

      4/2/25 4:03:15 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Interim CEO Smith Ian F

      4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

      3/20/25 6:19:44 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    Leadership Updates

    Live Leadership Updates

    See more
    • Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

      – Mr. Olson brings two decades of successful corporate business development experience with an emphasis on rare diseases and RNA therapeutics – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced the appointment of Eric Olson as Chief Business Officer. Mr. Olson has two decades of experience in life sciences business development and strategy with a track record of success, completing numerous transactions to maximize value for company pipelines across a variety of therapeutic areas, including rare genetic diseases, neurology and ophthalmology. In his new role, Mr. Ol

      9/4/24 8:00:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

      – Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke's leadership team, Mr. Hoitt will be responsible for overseeing the Company's global commercial strategy for STK-001. Recently annou

      4/17/24 8:00:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics Appoints Ian Smith to its Board of Directors

      – Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Ian Smith to its Board of Directors effective September 19. "Ian brings more than two decades of significant executive management experience in the life sciences industry, with a strong track record of successfully building valuable biotech businesses," said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. "His div

      9/20/23 4:30:00 PM ET
      $FHTX
      $SLDB
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $STOK
    Financials

    Live finance-specific insights

    See more
    • GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

      Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen

      2/18/25 6:00:00 AM ET
      $BIIB
      $PRAX
      $STOK
      $WGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Retail: Computer Software & Peripheral Equipment
    • Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

      – Alignment achieved with U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for EMPEROR – – One-year study of zorevunersen will evaluate reductions in major motor seizure frequency as well as improvements in behavior and cognition in children and adolescents ages 2 to <18 years old – – FDA Breakthrough Therapy designation positions zorevunersen on efficient development path; Company plans to start Phase 3 in mid-2025 – – Webcast and conference call for analysts and investors at 8:00AM Eastern Time today – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein

      1/7/25 7:00:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

      Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that its management team will host a webcast and conference call for investors and analysts to discuss successful alignment with global regulatory agencies related to a Phase 3 study of zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome. The webcast will be conducted Tuesday, January 7, 2025 at 8:00am Eastern Time and can be accessed from the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. Research analysts who plan to join th

      1/6/25 4:30:00 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Stoke Therapeutics with a new price target

      Chardan Capital Markets initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $24.00

      12/20/24 7:51:37 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners resumed coverage on Stoke Therapeutics with a new price target

      Leerink Partners resumed coverage of Stoke Therapeutics with a rating of Outperform and set a new price target of $18.00

      10/14/24 7:42:47 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics upgraded by TD Cowen

      TD Cowen upgraded Stoke Therapeutics from Market Perform to Outperform

      3/26/24 8:09:24 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care